{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:26:59Z","timestamp":1792718819671,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010023","name":"Natural Science Research of Jiangsu Higher Education Institutions of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010023","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.clml.2020.12.008","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T12:47:41Z","timestamp":1608209261000},"page":"e227-e247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed\/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"21","author":[{"given":"Xueqian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqian","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.12.008_bib1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/bjh.14240","article-title":"Detection of prognostic factors in children and adolescents with Burkitt and diffuse large B-cell lymphoma treated with the AIEOP LNH-97 protocol","volume":"175","author":"Pillon","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.12.008_bib2","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1182\/blood-2014-11-551481","article-title":"How I treat acute lymphoblastic leukemia in older adolescents and young adults","volume":"125","author":"Curran","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.008_bib3","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2020.12.008_bib4","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","article-title":"Modern therapy of acute lymphoblastic leukemia","volume":"29","author":"Bassan","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.12.008_bib5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4143\/crt.2013.047","article-title":"Clinical outcome of relapsed or refractory Burkitt lymphoma and mature b-cell lymphoblastic leukemia in children and adolescents","volume":"46","author":"Kim","year":"2014","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.clml.2020.12.008_bib6","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Programa Espa\u00f1ol de Tratamiento en Hematologia Group. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.12.008_bib7","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.008_bib8","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3109\/10428194.2012.677534","article-title":"Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia","volume":"53","author":"Anoop","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.12.008_bib9","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/annonc\/mdw029","article-title":"Breakthrough therapies in B-cell non-Hodgkin lymphoma","volume":"27","author":"Cheah","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.12.008_bib10","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1200\/JCO.2012.41.6768","article-title":"Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.12.008_bib11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-019-0786-6","article-title":"Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma","volume":"12","author":"Yu","year":"2019","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2020.12.008_bib12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2567.2007.02752.x","article-title":"CD22: an inhibitory enigma","volume":"123","author":"Walker","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/j.clml.2020.12.008_bib13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.it.2012.04.010","article-title":"CD22 and Siglec-G in B cell function and tolerance","volume":"33","author":"Poe","year":"2012","journal-title":"Trends Immunol"},{"key":"10.1016\/j.clml.2020.12.008_bib14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.immunol.15.1.481","article-title":"CD22, a B lymphocyte\u2013specific adhesion molecule that regulates antigen receptor signaling","volume":"15","author":"Tedder","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.clml.2020.12.008_bib15","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","article-title":"Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin","volume":"17","author":"Ricart","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.12.008_bib16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2141.2009.07701.x","article-title":"CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma","volume":"146","author":"Takeshita","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.12.008_bib17","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","article-title":"Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies","volume":"103","author":"DiJoseph","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.008_bib18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1158\/1078-0432.CCR-05-1905","article-title":"Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin\u2019s B-cell lymphoma","volume":"12","author":"DiJoseph","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.12.008_bib19","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/hep.30222","article-title":"Liver complications following treatment of hematologic malignancy with anti-CD22-calicheamicin (inotuzumab ozogamicin)","volume":"69","author":"McDonald","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.clml.2020.12.008_bib20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","article-title":"Management of important adverse events associated with inotuzumab ozogamicin: expert panel review","volume":"53","author":"Kebriaei","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.12.008_bib21","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.clml.2020.12.008_bib22","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.12.008_bib23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.1840040121","article-title":"Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors","volume":"4","author":"Mcdonald","year":"1984","journal-title":"Hepatology"},{"key":"10.1016\/j.clml.2020.12.008_bib24","first-page":"197","article-title":"Hepatic veno-occlusive disease -- liver toxicity syndrome after bone marrow transplantation","volume":"10","author":"Shulman","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.12.008_bib25","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2014"},{"key":"10.1016\/j.clml.2020.12.008_bib26","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin\u2019s lymphoma: results of a phase I study","volume":"28","author":"Advani","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.12.008_bib27","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","article-title":"Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"33","author":"Bhojwani","year":"2019","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2020.12.008_bib28","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1182\/blood-2019-126472","article-title":"A\u00a0retrospective study on inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukemia (ALL)","volume":"134","author":"Brivio","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2020.12.008_bib29","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1182\/blood-2019-122411","article-title":"A\u00a0phase I study of single-agent inotuzumab ozogamicin in pediatric CD22-positive relapsed\/refractory acute lymphoblastic leukemia: preliminary results of the ITCC-059 study","volume":"134","author":"Brivio","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.008_bib30","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1016\/j.clml.2019.07.038","article-title":"Inotuzumab ozogamicin salvage monotherapy for the treatment of relapsed\/refractory acute B-cell lymphoblastic leukemia","volume":"19","author":"Dar\u00e7\u0131n","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.12.008_bib31","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/bloodadvances.2016001925","article-title":"Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1\/2 study","volume":"1","author":"DeAngelo","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2020.12.008_bib32","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bjh.14094","article-title":"A\u00a0phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy","volume":"174","author":"Goy","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.12.008_bib33","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.12.008_bib34","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2020.12.008_bib35","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood-2019-128977","article-title":"A\u00a0phase 2 trial of inotuzumab ozogamicin (InO) in children and young adults with relapsed or refractory (R\/R) CD22+ B-acute lymphoblastic leukemia (B-ALL): results from Children\u2019s Oncology Group protocol AALL1621","volume":"134","author":"O\u2019Brien","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.008_bib36","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/pbc.24721","article-title":"Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia","volume":"61","author":"Rytting","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2020.12.008_bib37","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1111\/j.1349-7006.2010.01601.x","article-title":"Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy","volume":"101","author":"Ogura","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2020.12.008_bib38","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2020.12.008_bib39","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/pbc.25353","article-title":"Hematopoietic stem cell transplantation following unsuccessful salvage treatment for relapsed acute lymphoblastic leukemia in children","volume":"62","author":"Inagaki","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2020.12.008_bib40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies","volume":"135","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.008_bib41","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1055\/s-0039-1698763","article-title":"Efficacy and safety of defibrotide for the treatment of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"45","author":"Yang","year":"2019","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.clml.2020.12.008_bib42","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","article-title":"Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment","volume":"22","author":"Dalle","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.12.008_bib43","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.12.008_bib44","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1002\/cncr.31720","article-title":"Chemoimmunotherapy with inotuzumab ozogamicin combined. with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage","volume":"124","author":"Jabbour","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.12.008_bib45","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood.V128.22.1634.1634","article-title":"A\u00a0phase 1 trial of inotuzumab in combination with CVP (cyclophosphamide, vincristine, prednisone) for relapsed\/refractory CD22+ acute leukemia (SWOG 1312)","volume":"128","author":"Advani","year":"2016","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020310144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020310144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T06:36:32Z","timestamp":1730529392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020310144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2152265020310144"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.12.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed\/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}